S. Atkinson

发表

A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder

H. Eriksson, I. Eggens, ArifUllah Khan, 2011, Journal of clinical psychopharmacology.

A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2014, Journal of child and adolescent psychopharmacology.

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

R. Findling, R. Abbas, D. Wajsbrot, 2017, Journal of child and adolescent psychopharmacology.

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.

I. Pedley, R. McMenemin, R. Pearson, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Michael R. Johnson, M. Quirk, J. Zajecka, 2016, Neuropsychopharmacology.

26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic).

R. Findling, M. Bachinsky, P. Chappell, 2022, Journal of child and adolescent psychopharmacology.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.

H. Eriksson, C. Datto, R. Buynak, 2010, The international journal of neuropsychopharmacology.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.

F. She, ArifUllah Khan, S. Pathak, 2013, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials

S. R. Jones, D. Wajsbrot, Sara Ramaker, 2018, CNS Spectrums.

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

S. Ball, C. Goldberger, M. Bangs, 2015, Journal of clinical psychopharmacology.

Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence–powered analysis of 12-lead intake electrocardiogram

T. Biering-Sørensen, M. Maleckar, F. Braunschweig, 2021, Cardiovascular Digital Health Journal.

Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.

R. Findling, M. Bachinsky, P. Chappell, 2022, Journal of child and adolescent psychopharmacology.

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

S. Ball, C. Goldberger, M. Bangs, 2015, Journal of clinical psychopharmacology.